Evaluates aspirin use for primary vs secondary cardiovascular prevention. Secondary prevention: clear benefit in all patients with established CVD. Primary prevention: benefit outweighs harm only in patients aged 40–70 with high CVD risk (≥10% 10-year risk) and low bleeding risk. USPSTF recommends against initiating aspirin in adults ≥60 for primary prevention.
Use the full interactive calculator below, or